Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease

<p>I. Introduction</p><p>1. Introduction and Technical Survey; J. Robin Harris and Nathaniel G. Milton <p>II. Basic Science</p><p>2. Fibril Formation by Short Synthetic Peptides; Andrew Smith </p><p>3. In vitro Oligomerization and Fibrillogenesis of Amyloid-beta Peptides; Núria  Benseny-Cases, Oksana Klementieva and Josep Cladera<p>4. Tau Fibrillogenesis; Nitin Chaudhary and Ramakrishnan Nagaraj<p>5. Prion protein Aggregation and Fibrillogenesis In vitro; Jan Stöhr</p><p>6. α-Synuclein Aggregation and Modulating Factors; Katerina E. Paleologou and Omar M. A. El-Agnaf</p><p>7. Pathological Self-aggregation of β₂-microglobulin: A Challenge for Protein Biophysics; Gennaro Esposito, Alessandra Corazza, and Vittorio Bellotti</p><p>8. Islet amyloid polypeptide – Aggregation and fibrillogenesis in vitro and its Inhibition; Janine Seeliger and Roland Winter</p><p>9. Mechanisms of Transthyretin Aggregation and Toxicity; Robert J. Gasperini, David W. Klaver, Xu Hou, Marie-Isabel Aguilar and David H. Small<p>10. Fibrillogenesis of Huntingtin and Other Glutamine Containing Proteins; Yuri L. Lyubchenko, Alexey V. Krasnoslobodtsev and Sorin Luca</p><p>11. Aggregation and Fibrillogenesis of Proteins not Associated with Disease – A few Case Studies; Moritz Lassé, Juliet A. Gerrardand F. Grant Pearce<p>12. Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs; Alagiri Srinivasan</p><p>13. Experimental inhibition of fibrillogenesis and neurotoxicity by amyloid-beta (Aβ) and other disease-related peptides/proteins by plant extracts and herbal compounds; Suresh Kumar, Edward  Okello and J. Robin Harris</p><p>III. Clinical Science: The Cerebral and Systemic Amyloid Diseases</p><p>Pathogenesis and therapeutic consideration of the major disorders<p>14. Alzheimer’s  Disease; Vanessa J. De-Paula, Marcia Radanovic, Breno S. Diniz, Orestes V. Forlenza</p><p>15. Modeling the Polyglutamine Aggregation Pathway in Huntington’s Disease: from Basic Studies to Clinical Applications;<br> Keizo Sugaya</p><p>16. Parkinson’s Disease; Timothy R. Mhyre, James T. Boyd, Robert W.  Hamill, and Kathleen Maguire-Zeiss</p><p>17. Human Prion Diseases: From Kuru to Variant Creutzfeldt-Jakob Diseasae; Beata Sikorska and Paweł P. Liberski</p><p>18. Animal Prion Diseases; Otto Windl and Mike Dawson</p><p>19. β₂-microglobulin Amyloidosis; Dorthe B. Corlin and Niels H.H. Heegaard</p><p>20. Systemic AA Amyloidosis; Jennifer H Pinney and Helen J Lachmann</p><p>21. Familial Amyloidotic Polyneuropathy and Transthyretin; Takamura Nagasaka 22. The Challenge of Systemic Immunoglobulin Light-chain Amyloidosis (AL); Giovanni Palladini and Raymond L Comenzo</p>